3-Methoxyamphetamine

Use and effects

According to Alexander Shulgin, 3-MA showed no central or psychedelic effects in humans at a total dose of 50mg (25mg orally twice separated by 3hours). However, sympathomimetic effects have occurred with the drug at an oral dose of 25mg in humans.

Pharmacology

Pharmacodynamics

3-MA has similar effects in animal drug discrimination tests to para-methoxyamphetamine (PMA; 4-MA). However, it has a different balance of monoamine release, being a combined serotonin–norepinephrine–dopamine releasing agent (SNDRA) rather than a fairly selective serotonin releasing agent (SSRA) like PMA. 3-MA's values for induction of monoamine release are 58.0nM for norepinephrine and 103nM for dopamine in rat brain synaptosomes, whereas the value for serotonin was not reported.

The drug has shown relatively low affinity for serotonin receptors in the rat stomach fundus strip, intermediate between amphetamine and amphetamine psychedelics like DOM and DOB. In another study, its affinities (Ki) for the serotonin 5-HT1 and 5-HT2 receptors were 2,660nM and 7,850nM, respectively. 3-MA is also a weak agonist of the human trace amine-associated receptor 1 (TAAR1), with micromolar potency.

3-MA produced hyperlocomotion, a psychostimulant-like effect, in rodents similarly to amphetamine and PMA. It also produced hyperthermia and myoclonus, which are serotonin syndrome-associated effects, in rodents similarly to PMA.

3-MA produces gepefrine (3-hydroxyamphetamine), a sympathomimetic agent, as one of its major metabolites.

Chemistry

Analogues

The 2-aminoindane analogue of 3-MA is 5-methoxy-2-aminoindane (MEAI; 5-MeO-AI).

History

3-MA has appeared on the illicit market as a designer drug alternative to MDMA similarly PMA in the late 1980s and early 1990s, although far more rarely than PMA. Subsequently, it reappeared on the market, specifically via online sellers, in December 2021.

References

References

1. "Acid Addition Salts of D-(+)-1-(3-Hydroxyphenyl)-2-Aminopropane and Their Manufacture and Use".
2. "м-Метоксиамфетамин (3-Methoxyamphetamine)".
3. (2011). "[[The Shulgin Index". Transform Press.
4. (1991). "PiHKAL: A Chemical Love Story". Transform Press.
5. Schelling, J.L., Dufour, R.J., Jequier, E. (1974) Vasopressor effect of 3-methoxyamphetamine in man. Vortr. Symp. Meeting Date 1970, pp 175-183. "Like other amphetamines, 3-methoxyamphetamine (I) [17862-85-0] had a transient pressor effect on man. The minimal effective dose on oral administration was 25 mg. Differences between that dose and a placebo were significant in young normotensive subjects. The acute response of older patients with chronic hypotension to the same dose was unpredictable. Unlike other amphetamines, this drug did not produce any tachycardia. There was no sustained elevation of blood pressure when the drug was given twice daily for 3 days. The urinary excretion of catechol amines was unchanged."
6. (May 1985). "Structure-activity studies on methoxy-substituted phenylisopropylamines using drug discrimination methodology". Pharmacology, Biochemistry, and Behavior.
7. (July 2008). "Dopamine Transporters: Chemistry, Biology and Pharmacology". Wiley.
8. (May 1976). "Comparative actions of monomethoxyamphetamines on the release and uptake of biogenic amines in brain tissue". The Journal of Pharmacology and Experimental Therapeutics.
9. (May 1976). "Pharmacological evidence for the central serotonergic effects of monomethoxyamphetamines". The Journal of Pharmacology and Experimental Therapeutics.
10. (December 1981). "Photoelectron spectra of psychotropic drugs. 6. Relationships between the physical properties and pharmacological actions of amphetamine analogues". J Med Chem.
11. (March 1980). "Serotonin receptor affinities of psychoactive phenalkylamine analogues". J Med Chem.
12. (January 1987). "Central serotonin receptors as targets for drug research". J Med Chem.
13. (December 2011). "Trace amine-associated receptor 1 is a stereoselective binding site for compounds in the amphetamine class". Bioorg Med Chem.
14. (1978). "The Psychopharmacology of Hallucinogens". Pergamon.
15. (May 1976). "Pharmacological evidence for the central serotonergic effects of monomethoxyamphetamines". J Pharmacol Exp Ther.
16. (February 1981). "The metabolism of 3-methoxyamphetamine in dog, monkey and man". Xenobiotica; the Fate of Foreign Compounds in Biological Systems.
17. (1993). "Novel serotonergic agents". Drug des Discov.
18. (June 2001). "A re-examination of the mono-methoxy positional ring isomers of amphetamine, methamphetamine and phenyl-2-propanone". Forensic Science International.